

Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment

Jinyong Kim^{1*} & Euijin Chang^{1*}, Song Yi Park¹, Dae-Won Lee¹, Chang Kyung Kang¹,
Pyoeng Gyun Choe¹, Nam Joong Kim¹, Myoung-don Oh¹, Wan Beom Park¹ & Kyung-Hun
Lee^{1,2}, Seock-Ah Im^{1,2}

Author affiliations

¹ **Department of Internal Medicine, Seoul National University College of Medicine,
Seoul National University Hospital, Seoul, Korea**

² **Cancer Research Institute, Seoul National University, Seoul, Korea**

***Co-first authors**

Correspondence to

Kyung-Hun Lee, MD, PhD

Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro,
Jongro-gu, Seoul 03080, Republic of Korea

Tel: 82-2-2072-7207, E-mail kyunghunlee@snu.ac.kr

Wan Beom Park, MD, PhD

Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro,
Jongro-gu, Seoul 03080, Republic of Korea

Tel: 82-2-2072-3596, E-mail wbpark1@snu.ac.kr

Author Contributions

K.L. and W.P. conceptualized the study and set methodology. J.K. and E.C. performed data collection, formal analysis and interpretation. All authors performed data curation. K.L. and W.P. supervised the study. J.K. and E.C. wrote original manuscript. All authors reviewed and provide final approval of the manuscript.

Keywords: COVID-19, SARS-CoV-2 vaccines, breast cancer, adjuvant chemotherapy, anti-spike antibody

1 **Abstract**

2 *Background*

3 Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals and
4 patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have
5 been developed and used for patients with cancer, but scarce data is available on their
6 efficacy in patients under active anti-cancer therapies.

7 *Materials and Methods*

8 In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the
9 anti-spike protein subunit 1 of SARS-CoV-2 after vaccination in early breast cancer patients
10 with concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no
11 treatments.

12 *Results*

13 Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with
14 early breast cancer, regardless of the type of anticancer therapies. However, the post-
15 vaccination serum anti-spike antibody titers were significantly lower in the patients under
16 cytotoxic chemotherapy.

17 *Conclusion*

18 Our study emphasizes the importance of the personalized risk stratification and consideration
19 for booster doses in more vulnerable populations.

20

21 **Implications for Practice**

22 In this article, we present rare data on the homogeneous population of patients with early

23 breast cancer under active anti-cancer treatments. The patients showed adequate serologic
24 responses against SARS-CoV-2 virus after standard doses of vaccination without serious
25 adverse events in concurrence with active adjuvant anti-cancer therapy. The patients
26 receiving concurrent cytotoxic chemotherapy, however, have significantly lower serum anti-
27 spike antibody titers than those under non-cytotoxic anti-cancer treatments or without
28 treatments. Selection of the COVID-19 vaccines should be based on personalized risk
29 stratification considering the use of concurrent cytotoxic chemotherapy and the patient's
30 medical circumstances. Booster doses of vaccination could be considered for the vulnerable
31 population, such as elderly with comorbidities and the single standard dose of vaccination.

32

33

34 **Introduction**

35 Coronavirus disease 2019 (COVID-19) pandemic had affected over the world with 308
36 million confirmed cases and 5.49 million deaths as of January 12, 2022 ¹. Standard doses of
37 authorized vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
38 which included BNT162b2 vaccine (Pfizer–BioNTech (PZ)), mRNA-1273 vaccine
39 (Moderna), Ad26.COV2.S vaccine (Janssen)², and AZD1222 vaccine (Oxford-AstraZeneca
40 (AZ)), provided comparable efficacy in preventing symptomatic COVID-19 with the
41 acceptable safety profile³⁻⁶.

42 Patients with cancer have an increased mortality rate due to COVID-19, and are
43 considered as a prioritized group in need of vaccination by most authorized global guidelines
44 ⁷⁻¹². Nonetheless, patients with cancer under systemic treatments were largely excluded from
45 the previous clinical trials conducted to assess the efficacy of the COVID-19 vaccines.
46 Although recent studies reported that the standard dose of vaccine induced adequate
47 responses in patients with cancers, data on each specific solid cancer needs further
48 investigation ^{13,14}.

49 Breast cancer is the leading cause of the cancer deaths in female ¹⁵. Especially, the early
50 breast cancer confined to the breast and regional lymph nodes accounts for majority of the
51 total cases ^{16,17}. Treatments of early breast cancer are usually composed of various modalities
52 including surgery, radiotherapy, hormonal therapy, molecular targeted therapy, and
53 chemotherapy with corticosteroid prophylaxis ¹⁶. Thus, the effect of COVID-19 vaccination
54 should be reevaluated among the patients with early breast cancer who are currently under
55 different anti-cancer treatments.

56 This study is a prospective study evaluating the serologic responses from standard doses
57 of COVID-19 vaccines in the patients with early breast cancer, by comparing the antibody

58 responses in the patients on cytotoxic chemotherapy with those in the patients on the other
59 anti-cancer treatments. We also investigated whether the adjunct corticosteroid affected the
60 immunologic responses to vaccines in the patients with early breast cancer.

61

62 **Materials and methods**

63 *Study design and subjects*

64 This is a prospective, longitudinal cohort study that commenced recruitment in April 2021
65 at Seoul National University Hospital. Early breast cancer patients who are 20 years or older
66 with the past or current history of systemic anti-cancer treatments for breast cancer, including
67 cytotoxic chemotherapy, molecule-targeted therapy, and endocrinal therapy were enrolled.
68 Early breast cancer was defined as the disease confined to the breast with or without regional
69 lymph node involvement, and without distant metastatic disease. The patients who were
70 currently under chemotherapy within 28 days of vaccination were included in the cytotoxic
71 chemotherapy group; patients under targeted therapy and endocrinal therapy were in non-
72 cytotoxic anti-cancer treatment group; patients who did not receive any anti-cancer treatment
73 within 28 days of vaccination were in control group. The patients received standard doses of
74 vaccines, which were either two doses of PZ, Moderna, AZ, or a single dose of Janssen. The
75 patients who had active infectious diseases or received immune-suppressants or organ
76 transplant were excluded.

77 The chemotherapy regimen included anthracyclines, cyclophosphamide, docetaxel,
78 paclitaxel, carboplatin, and capecitabine. Molecular target agents included trastuzumab and
79 pertuzumab. Hormonal therapies were chosen among tamoxifen, letrozole, and anastrozole
80 depending on the patient's menopausal status and clinical conditions. The association

81 between corticosteroid use and vaccination was also assessed in the patients who used
82 corticosteroid over 10mg of prednisolone or equivalent dose within 14 days of vaccination¹⁴.

83 Our primary endpoint was the immunogenicity of the COVID-19 vaccine in the patients
84 with early breast cancer under active systemic anti-cancer treatment, defined by the
85 proportion of patients who achieved positive anti-spike (anti-S1) antibody titer after
86 vaccination. Secondary outcomes included the association of the prior use of corticosteroids
87 to immunogenicity of vaccines. Clinical data and samples were collected before the
88 vaccination, between 21 to 28 days after the first and the second dose of vaccination,
89 respectively. The study was approved by the Institutional Review Board (IRB No. 2103-121-
90 1206). Written informed consent was obtained from all participants prior to vaccination. All
91 the data from the patients were anonymized and de-identified prior to analysis.

92

93 *S1-reactive IgG ELISA*

94 We evaluated the antibody responses at baseline and at 3 weeks after each vaccination. We
95 semi-quantitatively measured the concentration of the immunoglobulin G against the anti-S1
96 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Enzyme-linked
97 immunosorbent assay (anti-S1 IgG ELISA) (Euroimmun, Lübeck, Germany) according to the
98 manufacturer's instructions. The immunoassay was granted Emergency Use Authorization by
99 the US Food and Drug Administration. The cut-off index (COI) of optical density ratio (OD
100 ratio) greater than or equal to 1.1 was considered seropositive; COI lower than 0.8 was
101 considered negative; and the rest was considered borderline according to the manufacturer's
102 instructions. Borderline results were considered as negative for analysis.

103

104 *Statistical analyses*

105 Categorical variables were summarized with the frequencies in number and rates in
106 percentages. Continuous variables were represented with the median values and ranges.
107 Differences were assessed using Mann-Whitney test for continuous variables and Pearson's
108 χ^2 or Fisher's exact test for categorical variables. P-values of <0.05 were considered
109 statistically significant. The association between treatment with cytotoxic chemotherapy and
110 the anti-S1 IgG OD ratio in post-vaccination serum was evaluated using a multivariate linear
111 regression model. The anti-S1 IgG OD ratio was set as the dependent variable and the
112 treatment with cytotoxic chemotherapy was set as the independent variable. Additional
113 covariates were age and type of vaccines. The association between treatment with cytotoxic
114 chemotherapy and the seropositivity based on OD ratio was evaluated using a logistic
115 regression model. Data and statistical analyses were performed in R version 4.1.2 and
116 RStudio version 2021.09.1.

117

118 **Results**

119 *Patient characteristics*

120 We recruited 112 patients with early breast cancer who received adjuvant cytotoxic
121 chemotherapy and at least one dose of COVID-19 vaccine. Twelve patients withdrew from
122 the study, and another twelve samples were not available for the analysis at the time of data
123 collection. One case was excluded because of the high baseline anti-S1 antibody level,
124 suggestive of COVID-19 infection prior to vaccination (Figure 1). Of all, 80.5% (70 of 87)
125 received PZ; 10.3% (9 of 87) received Moderna; 3.4% (3 of 87) received Janssen; 5.7% (5 of
126 87) received AZ. Except for the three patients who received single dose of Janssen, 84

127 patients received two doses of vaccines without cross-injection. The median interval between
128 the first and second vaccination was 42 days (range, 21-77). The median age of patients was
129 52 years (range 35-69) and all were female. Within 28 days of vaccination, 36.8% (32 of 87)
130 underwent cytotoxic chemotherapy and 9.2% (8 of 87) had combination with targeted therapy.
131 Patients who received non-cytotoxic anti-cancer therapy were 42.5% (37 of 87). Only one
132 patient was under molecular targeted therapy, and other 36 patients were under endocrinal
133 therapy. The patients who had no anti-cancer treatment within 28 days of vaccination were
134 20.7% (18 of 87). No serious adverse events were reported. The patient characteristics are
135 shown in Table1.

136

137 *Vaccine immunogenicity with active chemotherapy*

138 Overall, 96.6% (84 of 87) were seropositive after completion of vaccinations. After first
139 dose, 70.1% (61 of 87) were seropositive, and additional 25.3% (22 of 87) gained
140 seropositivity after second dose (Figure 2, Table S1). Three patients failed seroconversion;
141 two were in borderline range and one was seronegative. Two patients in borderline range
142 received two doses of PZ vaccine during adjuvant doxorubicin and cyclophosphamide
143 chemotherapy. The only seronegative patient received one dose of Janssen while on letrozole
144 (Table S2).

145 Only 31.2% (10 of 32) in the chemotherapy group, compared with 91.9% (34 of 37) in the
146 non-cytotoxic treatment group and 94.4% (17 of 18) in the control group, achieved the
147 adequate immunoglobulin level after the first dose. However, the majority (93.8%, 30 of 32)
148 of the patients in chemotherapy group achieved seropositivity after the second dose. In the
149 non-cytotoxic treatment group and control group, all patients who received two doses of
150 vaccination were seropositive. There was no significant difference in seroconversion rate

151 after the completion of vaccination among the cytotoxic chemotherapy group, non-cytotoxic
152 treatment group, and control group (93.8% vs. 97.3% vs. 100%, $p=0.234$). No significant
153 association was observed in seropositivity regarding age, types of vaccines, and treatments
154 with cytotoxic chemotherapy (Table S3).

155 Anti-S1 antibody levels increased gradually with each vaccination in all patients, with more
156 than 50 folds after the first dose and 137 folds after the second dose (Figure S1). Both mRNA
157 or adenovirus vector vaccines showed significant increase in antibody titers (Figure S2), and
158 no significant difference was observed in the anti-S1 antibody titer at each time point.

159 When the antibody titers in the chemotherapy group, the non-cytotoxic treatment group,
160 and the control group were compared, the antibody titers also significantly and gradually
161 increased in all groups after the first and second vaccinations. Despite similar baseline levels,
162 however, significantly lower magnitudes of antibody titers was observed in patients who had
163 concurrent cytotoxic chemotherapy, compared to those in the non-cytotoxic treatment group
164 or those in the control group after first vaccination (cytotoxic chemotherapy vs. non-cytotoxic
165 treatment vs. control, 10.7 vs. 84.2 vs. 69.8-fold increase respectively, $p<0.001$) and second
166 vaccination (95.4 vs. 142.1 vs. 132.4-fold increase respectively, $p<0.001$ for cytotoxic vs.
167 non-cytotoxic and $p=0.005$ for cytotoxic vs. control) (Figure 3, Table 2). In the linear
168 regression and multiple regression analyses adjusted for age, the treatment with cytotoxic
169 chemotherapy remained as a significant factor for predicting low anti-S1 antibody titer
170 ($p<0.001$). No significant association was observed between the antibody titers with types of
171 vaccines (Table S4, S5).

172

173 *Vaccine immunogenicity with corticosteroid use*

174 Corticosteroid was used within 14 days before the vaccination in 20.9% (18 of 87) of the
175 patients, all of whom were in the chemotherapy group. The association between
176 corticosteroid use and antibody titer was only assessed in chemotherapy group to control the
177 effect of chemotherapy to immunogenicity. There was no significant difference in the
178 antibody titers between the patients who received corticosteroid in concurrence with
179 chemotherapy and those who only received chemotherapy at the time of vaccination (Figure
180 4).

181

182 **Discussion**

183 In this prospective study, standard regimen of COVID-19 vaccination generated sufficient
184 amount of IgG antibody titers against SARS-CoV-2 virus in most of the early breast cancer
185 patients who had adjuvant anti-cancer treatments. The rate of seropositivity was numerically
186 comparable to that of the previous studies performed in patients with cancer ^{13,14,18,19}. It is
187 well known that the anti-spike antibody titer is correlated with the protection from COVID-
188 19 ²⁰⁻²³. The emergence of neutralizing antibodies at early onset was associated with the
189 shorter time for negative conversion of swab culture, while the lack of neutralizing antibody
190 was associated with a fatal outcome in symptomatic COVID-19 patients ²⁰. Known as a good
191 surrogate marker of neutralizing antibody titers ^{20,23}, the anti-spike antibody levels measured
192 with EUROIMMUN ELISA kit also reported strong positive correlation with the neutralizing
193 antibody titers assessed by a microneutralization assay ²¹. All in all, patients with breast
194 cancer under concurrent adjuvant cytotoxic chemotherapy, when compared with those under
195 molecular targeted therapy, endocrine therapy, or no anti-cancer treatments, were capable of
196 acquiring adequate protections against COVID-19 infection after vaccinations, irrespective of
197 age and types of vaccines.

198 Cytotoxic chemotherapy, however, was significantly associated with lower IgG antibody
199 titers after both first and second dose of vaccinations despite the equivalent seroconversion
200 rate. About 7.8-fold difference was observed between the cytotoxic chemotherapy group and
201 non-cytotoxic treatment group after the first dose of vaccine, which decreased to 1.5-folds
202 after the second dose. A cohort study reported that the anti-spike IgG titers of patients with
203 solid cancer was 3.7-folds lower than those of healthy relatives after the second dose of Pfizer
204 vaccination ¹³. Moreover, two of the patients were under adjuvant cytotoxic chemotherapy
205 before PZ vaccine showed borderline range of anti-S1 IgG levels. In PZ vaccination trial, the
206 median IgG titer was statistically significantly lower in the patients under active cancer
207 treatments with healthy controls ¹³. Booster dose of vaccinations may be considered in the
208 cancer patients under active cytotoxic treatments for a robust protection against SARS-CoV-2.

209 The only patient who was seronegative had received one dose of Janssen while on
210 endocrinal therapy, and had completed cytotoxic chemotherapy 47 days before vaccination.
211 Meanwhile, two other patients who had received Janssen vaccine experienced sufficient
212 seroconversion after the first dose between cycles of cytotoxic chemotherapies. One possible
213 speculation would be their ages. The seronegative patient was over 65 years old while other
214 two seropositive patients were in their 40s and 50s. In the phase I/II trial of Janssen vaccine,
215 the participants of 60 years or older had lower incidence of seroconversion ²⁴. In the subgroup
216 analysis of ENSEMBLE trial, lower efficacy of preventing the severe-critical COVID-19 was
217 observed among participants of 60 years or older with comorbidities ⁶. Individual medical
218 circumstances should be taken into account in choosing the type of vaccines, and booster
219 doses should be considered for vulnerable populations.

220 The non-cytotoxic treatment group treated with endocrinal therapy and monoclonal anti-
221 HER-2 therapy showed similar seroconversion rates and anti-S1 antibody titers when

222 compared to control group. Previous study reported higher rates of post-vaccination
223 seroconversion in patients on endocrine therapy including ovarian function suppression and
224 aromatase inhibitors compared with the other groups¹⁸. Only scarce data was available
225 regarding the impact of the trastuzumab to the efficacy of the vaccines. One study about
226 influenza vaccination reported that breast cancer patients receiving adjuvant trastuzumab had
227 sufficient increase of immunogenicity and equivalent serological protection rate as healthy
228 controls²⁵.

229 It had been widely believed that the use of systemic corticosteroid may affect T and B cell
230 functions. For example, patients with sustained high-dose corticosteroids were associated
231 with poor pneumococcal polysaccharide vaccine response and more infections²⁶. In our study,
232 corticosteroids over 10mg of prednisolone or equivalent dose within 14 days of vaccination
233 apparently seemed to diminish the amount of antibody titers. But corticosteroids were
234 administered as the premedication for taxanes, and none of the control group used
235 corticosteroids. When the factor of cytotoxic chemotherapy was adjusted, there was no
236 difference in the antibody titers with corticosteroid treatments. A recent study also reported
237 that the short term use of corticosteroids significantly relieved side effects without hindering
238 immunogenicity after the first dose of AZ vaccine²⁷. In our study, adjunctive corticosteroids
239 were used shortly, and thus minimally impeded the immunologic responses driven by
240 vaccines.

241 Our data is limited by the relatively small number of patients, especially those who had
242 adenovirus vector vaccines. Unfortunately, only one patient was treated with trastuzumab that
243 the analysis of the effect of molecular target therapy on immunogenicity of vaccines was
244 unavailable. Immune checkpoints inhibitors, which are not yet approved as adjuvant
245 treatment for breast cancer, were not included in the study. However, this study was

246 successful in recruiting a homogeneous population of the early breast cancer patients
247 undergoing adjuvant anti-cancer treatments. We also evaluated the effects of corticosteroid
248 use to the seroconversion, which is commonly used in adjunct to cytotoxic chemotherapy.
249 Another pitfall was the possibility of the seroconversion by asymptomatic COVID-19
250 infections, because the regular COVID-19 PCR screenings were not done. T cell responses,
251 known as important in immunity against COVID-19, were also not evaluated. Further studies
252 with more patient data would strengthen our knowledge in understanding the immunologic
253 responses after vaccination in the patients with cancer.

254

255

256 **Conclusion**

257 Patients with early breast cancer undergoing adjuvant anti-cancer therapy showed adequate
258 serologic responses against SARS-CoV-2 virus after vaccination without serious adverse
259 events. Selection of the COVID-19 vaccines should be personalized, taking the patient's
260 medical circumstances into account. Booster doses of vaccination could be considered for the
261 vulnerable populations.

262

263 Reference:

264 1. Coronavirus Disease (COVID-19). (January 12, 2022)

265 2. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19
266 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. *Nat*
267 *Rev Immunol*. Oct 2021;21(10):626-636. doi:10.1038/s41577-021-00592-1

268 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA

- 269 Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27):2603-2615.
270 doi:10.1056/NEJMoa2034577
- 271 4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19
272 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled
273 trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397(10269):99-111.
274 doi:10.1016/S0140-6736(20)32661-1
- 275 5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
276 CoV-2 Vaccine. *New England Journal of Medicine*. 2020;384(5):403-416.
277 doi:10.1056/NEJMoa2035389
- 278 6. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
279 Vaccine against Covid-19. *New England Journal of Medicine*. 2021;384(23):2187-2201.
280 doi:10.1056/NEJMoa2101544
- 281 7. NCCN. Cancer and COVID-19 Vaccination version 4.0. Accessed January 12, 2022,
282 [https://www.nccn.org/docs/default-source/covid-19/2021_covid-](https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70)
283 [19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70](https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70)
- 284 8. Marina Chiara Garassino NG, Petros Grivas, Karin Jordan, Francesca Lucibello, Olivier
285 Mir, George Pentheroudakis, Florian Scotté, Marie von Lilienfeld-Toal, Giuseppe Curigliano,
286 John Haanen, Uwe Gerd Liebert, Florian Lordick, Ignacio Melero, Corinna Pietsch, and
287 Solange Peters. COVID-19 vaccination in cancer patients: ESMO statements. . Accessed
288 January 12, 2022, <https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination>
- 289 9. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in
290 patients with cancer. *Nature Medicine*. 2020/08/01 2020;26(8):1218-1223.
291 doi:10.1038/s41591-020-0979-0
- 292 10. Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region:
293 adverse outcomes in patients with cancer. *Nature Cancer*. 2020/08/01 2020;1(8):784-788.

294 doi:10.1038/s43018-020-0104-9

295 11. Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 Treatments and
296 Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium
297 (CCC19) Cohort Study. *Cancer Discov.* 2020;10(10):1514-1527. doi:10.1158/2159-8290.CD-
298 20-0941

299 12. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US
300 Patients With Cancer and COVID-19 Infection. *JAMA Oncology.* 2021;7(2):220-227.
301 doi:10.1001/jamaoncol.2020.6178

302 13. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of Seropositivity Following
303 BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment
304 for Cancer. *JAMA Oncology.* 2021;7(8):1133-1140. doi:10.1001/jamaoncol.2021.2155

305 14. Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies
306 against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the
307 CAPTURE study. *Nature Cancer.* 2021/10/27 2021;doi:10.1038/s43018-021-00274-w

308 15. 2020 G. Accessed January 12th, 2022, <https://gco.iarc.fr/>

309 16. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice
310 Guidelines for diagnosis, treatment and follow-up^{†}. *Annals of Oncology.*
311 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173

312 17. Kang SY, Kim YS, Kim Z, et al. Breast Cancer Statistics in Korea in 2017: Data from a
313 Breast Cancer Registry. *J Breast Cancer.* 4/ 2020;23(2):115-128.

314 18. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-
315 19 vaccination among patients with cancer. *Cancer Cell.* 2021/08/09/ 2021;39(8):1081-
316 1090.e2. doi:<https://doi.org/10.1016/j.ccell.2021.06.002>

317 19. Oosting S VdVA, GeurtsvanKessel CH, et al. Vaccination against SARS-CoV-2 in
318 patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors.

- 319 *Annals of Oncology* 2021;32(supplement 5):S1283-S1346.
- 320 20. Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-
321 2 in symptomatic COVID-19 is persistent and critical for survival. *Nature Communications*.
322 2021/05/11 2021;12(1):2670. doi:10.1038/s41467-021-22958-8
- 323 21. Dolscheid-Pommerich R, Bartok E, Renn M, et al. Correlation between a quantitative
324 anti-SARS-CoV-2 IgG ELISA and neutralization activity. *Journal of Medical Virology*.
325 2022;94(1):388-392. doi:<https://doi.org/10.1002/jmv.27287>
- 326 22. Salazar E, Kuchipudi SV, Christensen PA, et al. Relationship between Anti-Spike Protein
327 Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.
328 *bioRxiv*. 2020:2020.06.08.138990. doi:10.1101/2020.06.08.138990
- 329 23. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2
330 infection persist for months. *Science*. 2020;370(6521):1227-1230.
331 doi:doi:10.1126/science.abd7728
- 332 24. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1–2a Trial of
333 Ad26.COV2.S Covid-19 Vaccine. *New England Journal of Medicine*. 2021;384(19):1824-
334 1835. doi:10.1056/NEJMoa2034201
- 335 25. Joon TB, Digkas E, Wennstig A-K, et al. Influenza vaccination in breast cancer patients
336 during subcutaneous trastuzumab in adjuvant setting. *Breast Cancer Research and Treatment*.
337 2020/11/01 2020;184(1):45-52. doi:10.1007/s10549-020-05815-y
- 338 26. Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults
339 undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study.
340 *Arthritis Res Ther*. Jun 6 2015;17(1):151. doi:10.1186/s13075-015-0663-9
- 341 27. Yang J, Ko J-H, Baek JY, et al. Effects of Short-Term Corticosteroid Use on
342 Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine.
343 Perspective. *Frontiers in Immunology*. 2021-September-22

344 2021;12(3908)doi:10.3389/fimmu.2021.744206

345

346

347 **Figures and Tables**

348 Figure 1. Patient enrollment: Flowchart showing the patient enrollment and selection

349 Figure 2. Proportion of seroconversion in patients: Seroprevalence proportions in (A) all
350 early breast cancer patients, (B) with cytotoxic chemotherapy treatments, (C) with non-
351 cytotoxic treatments, and (D) without anti-cancer treatment.

352 Figure 3. Antibody titers with Anti-Cancer treatments: SARS-CoV-2 anti-S IgG antibody
353 titers after each dose of vaccinations in early breast cancer patients with cytotoxic
354 chemotherapy treatment, with non-cytotoxic treatment, and without anti-cancer treatment

355 Figure 4. Antibody titers with steroid treatments in chemotherapy group: Comparison of
356 SARS-CoV-2 anti-S IgG antibody titers after each dose of vaccinations with and without
357 corticosteroid treatments in cytotoxic chemotherapy group

358

359 Table 1. Patients' characteristics

360 Table 2. Antibody titers with Anti-Cancer treatments

361

362 **Supplementary Figures & Tables**

363 Figure S1. Antibody titers with vaccinations in all patients: SARS-CoV-2 anti-S IgG titers
364 after each dose of vaccinations in all early breast cancer patients

365 Figure S2. Antibody titers by vaccine types: SARS-CoV-2 anti-S IgG titers after each dose of
366 Adenoviral vaccines and mRNA vaccines

367 Figure S3. Antibody titers with steroid use: SARS-CoV-2 anti-S IgG titers in adjunct with
368 steroid use of more than or equivalent to prednisolone 10mg within 14 days of each dose of
369 vaccinations

370

371 Table S1. Seroprevalence of early breast cancer patients

372 Table S2. Characteristics of Patients who Failed Seroconversion

373 Table S3. Univariable logistic regression analysis for seropositivity

374 Table S4. Univariable Linear Regression Analysis for OD values

375 Table S5. Multiple Regression Analysis for OD values

376

377 **Data availability**

378 The datasets generated during and/or analyzed during the current study are available from the
379 corresponding author on reasonable request.

380

381 **Acknowledgments**

382 We thank Areum Jo for technical support.

383

384 **Fundings**

385 This work was supported in part by grant no 04-2021-0250 from the SNUH Research Fund
386 and by the Bio & Medical Technology Development Program of the National Research
387 Foundation (NRF) & funded by the Korean government (MSIT)(2021M3A9I2080498)

388

389 **Ethics declarations**

390 **Competing interests:** The authors declare no competing interests.

391

392

112 patients recruited

12 patients withdrew

100 patients enrolled


12 patients with
incomplete samplings

88 patients analyzed
with baseline samples


1 patients had prior
COVID-19 infection

87 patients finally
analyzed

Percentage of patients (%)



Anti-S1 IgG Titer (OD ratio)






Table 1. Patients' characteristics

	All	Cytotoxic chemotherapy	Non-cytotoxic anticancer treatment	No treatment
Total number	87	32 (36.8%)	37 (42.5%)	18 (20.7%)
Age (median, range)	52 (35-69)	52 (35-69)	49 (36-69)	51.5 (40-61)
Vaccine				
PZ	70 (80.5%)	22 (68.8%)	32 (86.5%)	16 (88.9%)
Moderna	9 (10.3%)	5 (15.6%)	4 (10.8%)	0 (0.0%)
Janssen	3 (3.4%)	2 (6.2%)	1 (2.7%)	0 (0.0%)
AZ	5 (5.7%)	3 (9.4%)	0 (0.0%)	2 (11.1%)
Anticancer treatments				
<28 days before the vaccination				
Chemotherapy only	24 (27.6%)	24 (75.0%)	0 (0.0%)	0 (0.0%)
Chemotherapy + targeted therapy	8 (9.2%)	8 (25.0%)	0 (0.0%)	0 (0.0%)
Targeted therapy	1 (1.1%)	0 (0.0%)	1 (2.7%)	0 (0.0%)
Endocrine therapy	36 (41.4%)	0 (0.0%)	36 (97.3%)	0 (0.0%)
No anticancer treatment	18 (20.7%)	0 (0.0%)	0 (0.0%)	18 (100.0 %)
Surgery <28 days before the vaccination				
	5 (5.7%)	5 (15.6%)	0 (0.0%)	0 (0.0%)

Corticosteroids

(≥ 10 mg prednisolone

equivalent) <14 days 18 (20.9%) 18 (56.2%) 0 (0.0%) 0 (0.0%)

before the

vaccination

Abbreviations: PZ, Pfizer; AZ, AstraZeneca.

Table 2. Antibody titers with Anti-Cancer treatments

Median (1st-3rd quartile)	All	Chemotherapy	Non-cytotoxic therapy	No treatment
OD ratio (baseline)	0.051 (0.019-0.081)	0.046 (0.028-0.089)	0.051 (0.037-0.069)	0.054 (0.031-0.080)
OD ratio (1 st dose)	2.680 (0.844-4.833)	0.494 (0.081-1.338)	4.294 (2.334-5.343)	3.769 (2.542-4.921)
OD ratio (2 nd dose)	7.028 (3.133-7.842)	4.388 (2.381-6.927)	7.249 (6.790-7.941)	7.152 (6.817-7.901)

Abbreviations: OD, optical density.